

2 **Fabrication and in situ characterization of microcapsules**  
3 **in a microfluidic system**

4 **T. X. Chu · A.-V. Salsac · D. Barthès-Biesel ·**  
5 **L. Griscom · F. Edwards-Lévy · E. Leclerc**

6 Received: 7 May 2012 / Accepted: 30 July 2012  
7 © Springer-Verlag 2012

8 **Abstract** We have designed a microfluidic system that  
9 enables both the fabrication of calibrated capsules and the in  
10 situ characterization of their mechanical properties. The  
11 fabrication setup consists of a double flow-focusing system.  
12 A human serum albumin aqueous solution is introduced in  
13 the central channel of a first Y-junction. Intercepted by the  
14 lateral flows of a hydrophobic phase, it is dispersed into  
15 microdroplets. A cross-linking agent is then introduced at a  
16 second Y-junction allowing a membrane to form around the  
17 droplets. The time of cross-linking is controlled by the  
18 length of a wavy channel located downstream of the second  
19 junction. A cylindrical microchannel finally enables to  
20 deform and characterize the capsules thus formed. The  
21 mechanical properties of the capsule membrane are  
22 obtained by inverse analysis. The results show that the drop  
23 size increases with the flow rate ratio between the central  
24 and lateral channels. The mean shear modulus of the cap-  
25 sules fabricated after 23 s of cross-linking is of the order of  
26 the surface tension between the two phases indicating that a  
27 reaction time of 23 s is too short for an elastic membrane to

form around the droplet. When the cross-linking time is 28  
increased to 60 s, the microcapsules surface is wrinkled, 29  
thus confirming that a solid membrane is formed around the 30  
drop. The mean shear modulus of the capsule membrane 31  
increases with the cross-linking time, which is in agreement 32  
with our previous chemical results and proves that a fine 33  
control of the mechanical properties is possible by choosing 34  
adequately the control parameters of the system. 35  
36

**Keywords** Flow-focusing microfluidic system · 37  
Capsule fabrication · Capsule characterization · 38  
Interfacial cross-linking · Two-phase flow · Serum albumin 39

37 **1 Introduction** 40

Capsules consisting of a liquid droplet enclosed within a 41  
thin deformable membrane are commonly used in the 42  
pharmaceutical (Kissel et al. 2006), cosmetic (Miyazawa 43  
et al. 2000) and food industries (Gibbs et al. 1999). 44  
Encapsulation allows the protection of the internal sub- 45  
stance and its release by controlling the membrane physical 46  
properties, porosity and break-up. 47

Most conventional encapsulation processes consist of 48  
two successive steps: fabrication of droplets and formation 49  
of the membrane around the droplet. Droplets may be 50  
formed by emulsification through mechanical agitation 51  
(Edwards-Lévy et al. 1993; Poux and Canselier 2004) or by 52  
extrusion and jet break-up (Gautier et al. 2011). The 53  
membrane may be created for example by protein cross- 54  
linking (Edwards-Lévy et al. 1993; Callewaert et al. 2009), 55  
complex coacervation (De Kruijff et al. 2004) or solvent 56  
evaporation (Sawalha et al. 2011). These different con- 57  
ventional techniques are largely used in industrial applica- 58  
tions because they allow the production of large quantities 59

A1 T. X. Chu · A.-V. Salsac · D. Barthès-Biesel · E. Leclerc (✉)  
A2 UMR CNRS 7338, Biomécanique et Bioingénierie,  
A3 Université de Technologie de Compiègne,  
A4 Compiègne Cedex, France  
A5 e-mail: eric.leclerc@utc.fr

A6 D. Barthès-Biesel  
A7 e-mail: dbb@utc.fr

A8 L. Griscom  
A9 UMR CNRS 8069, SATIE/BIOMIS,  
A10 ENS de Cachan antenne de Bretagne, Bruz, France

A11 F. Edwards-Lévy  
A12 UMR CNRS 7312, Institut de Chimie Moléculaire de Reims,  
A13 Faculté de Pharmacie, Université de Reims  
A14 Champagne-Ardenne, Reims, France

60 of capsules. However, they do not allow the fabrication of  
61 monodispersed capsules with homogeneous mechanical  
62 properties.

63 Microfluidic techniques have been recently proposed  
64 (Thorsen et al. 2001) to improve the homogeneity of  
65 microcapsule size and physical properties. Indeed, micro-  
66 fluidic devices allow the fabrication of calibrated drops  
67 through the injection of a disperse phase into a flowing  
68 immiscible continuous phase. Monodispersed microdrops  
69 can be produced using a T-junction microchip (Garstecki  
70 et al. 2006), a flow-focusing microchip (Yobas et al. 2006)  
71 or a microfluidic system based on co-axial cylindrical  
72 channels (Liu et al. 2009). The encapsulation process can  
73 be performed outside (outline) or inside (online) the sys-  
74 tem. For outline encapsulation, monodisperse microdrops  
75 formed at a cross-junction are collected in a reservoir  
76 containing a cross-linking solution (Huang et al. 2007; Yeh  
77 et al. 2009). The mechanical properties of the microcapsule  
78 membranes are not quite uniform because the droplets do  
79 not all have the same residence time in the reservoir. For  
80 online microcapsule fabrication, drops that are formed at  
81 the first cross-junction are stabilized at a second cross-  
82 junction, through which a cross-linking phase is injected.  
83 A downstream channel allows the control of the polymer-  
84 ization time of the microcapsules before collection (Zhang  
85 et al. 2006). The fabricated microcapsules then have a  
86 controlled membrane thickness and a controlled size.

87 Another issue is the determination of the membrane  
88 mechanical properties for which different methods have  
89 been proposed depending on the capsule size (Mercadé-  
90 Prieto and Zhang 2012). For example, a millimetric capsule  
91 can be compressed between two parallel plates and the  
92 compression force is then measured as a function of the plate  
93 separation (Carin et al. 2003). For micrometric capsules, a  
94 micropipette is used to measure the capsule length aspirated  
95 into the pipette under a given depression (Needham and  
96 Zhelev 1996). It is also possible to deform the microcapsule  
97 under a known force by means of an atomic force micro-  
98 scope (Fery and Weinkamer 2007). The latter techniques are  
99 difficult to implement because of the small capsule size.  
100 Conversely, the membrane elastic modulus of a microcap-  
101 sule population can be characterized by flowing a capsule  
102 suspension in a small channel, measuring the deformed  
103 profile and the velocity of the particles and analyzing the  
104 results by means of a numerical model of the mechanical  
105 process (Lefebvre et al. 2008; Chu et al. 2011).

106 The objective of this paper was to show that it is pos-  
107 sible to fabricate microcapsules in a microfluidic system  
108 under controlled conditions. The mechanical properties of  
109 the resulting capsules are then measured on-line with the  
110 aforementioned microfluidic technique. We have designed  
111 a microfluidic system that combines a double flow-focusing  
112 setup for capsule fabrication, ending with a microchannel

113 for the characterization of the microcapsule mechanical  
114 properties. Thanks to this device, microdroplets are created  
115 at a first Y-junction. A membrane is formed around the  
116 microdroplets by reticulation through the injection of a  
117 cross-linking agent at a second Y-junction. The cross-  
118 linking time is controlled by the length of the channel  
119 present after the second Y-junction. After cross-linking, the  
120 microcapsules are flowed in a glass capillary tube located  
121 downstream and embedded in the PDMS. The tube diam-  
122 eter is of the same order as the capsule characteristic size,  
123 so that the microcapsules deform under the shear stress.  
124 The microcapsule mechanical properties are characterized  
125 using the inverse method previously described. In this  
126 paper, we study the formation of microcapsules containing  
127 an aqueous solution enclosed in a network of cross-linked  
128 serum albumin (Edwards-Lévy 2011). The continuous  
129 phase is a hydrophobic liquid ester (Dragoxat) used in the  
130 cosmetic and pharmaceutical domains (Hurteaux et al.  
131 2005). The cross-linking agent is an acyl dichloride, the  
132 terephthaloyl chloride.

133 In Sect. 2, we present the fluid phases and the principle  
134 of microencapsulation using interfacial cross-linking of a  
135 protein, the microsystem design and fabrication technique,  
136 and the different aspects of the experimental procedure.  
137 The size of the capsules formed in the microsystem as well  
138 as the measured value of their membrane mechanical  
139 properties are detailed in Sect. 3. We finally discuss the  
140 process and conclude in Sect. 4.

## 2 Materials and methods 141

### 2.1 Fluid phases for the interfacial cross-linking of serum albumin 142-143

144 Interfacial cross-linking of proteins has been extensively  
145 studied by M.-C. Lévy and co-workers for the production  
146 of biocompatible and biodegradable microcapsules with  
147 tailored properties for pharmaceutical or cosmetical pur-  
148 poses (Edwards-Lévy et al. 1993, 1994, 2011; Lévy et al.  
149 1991; Andry et al. 1996). The method involves an acyla-  
150 tion reaction between the functional reactive groups of the  
151 protein present in the aqueous droplets of a water-in-oil  
152 emulsion and a bifunctional acylating reagent, such as an  
153 acyl dichloride, added to the external organic phase. Dur-  
154 ing the process, free amino groups, hydroxyl groups and  
155 acid groups of the protein become linked through amide  
156 bonds, ester bonds and anhydride bonds, respectively.  
157 Acylation takes place at the interface, and a membrane,  
158 made of a cross-linked protein network, is formed.


159 The reaction parameters, i.e. concentration of the protein  
160 and concentration of the cross-linking agent, reaction time  
161 and reaction pH, influence the membrane cross-linking

162 degree: they thus affect the degradation properties and  
 163 mechanical properties of the microcapsules. When the  
 164 process is conducted in an emulsion system, the emulsifi-  
 165 cation parameters, i.e. stirring speed, viscosities of the two  
 166 phases, nature and concentration of the surfactant, influ-  
 167 ence the mean size and the granulometric profiles of the  
 168 microcapsules. In the present study, the constitutive protein  
 169 is human serum albumin (HSA). The disperse phase consists  
 170 of a 20 % HSA solution prepared in a phosphate  
 171 buffer pH 9.8 to favor a rapid acylation. Its viscosity  
 172 is  $\mu = 3.31$  mPa s at 25 °C. The continuous phase is a  
 173 biocompatible liquid ester, 2-ethylhexyl 2-ethylhexanoate  
 174 (Dragoxat, Symrise). It is a hydrophobic fluid with vis-  
 175 cosity  $\mu = 3.5$  mPa s at 25 °C. It has been chosen as the  
 176 external phase because usual organic volatile solvents like  
 177 cyclohexane are deleterious to the polydimethylsiloxane  
 178 (PDMS) used to fabricate the microsystem. The surface  
 179 tension between the Dragoxat and the HSA solution is  
 180  $\gamma = 0.006$  N/m (Tensiometer Kruss DSA10 Mk2).

181 The cross-linking phase contains terephthaloyl chloride  
 182 (TC), an acyl dichloride, dissolved in Dragoxat: it cross-  
 183 links HSA at the surface of the aqueous droplets formed in  
 184 the microsystem. It is obtained by mixing 0.25 mg of TC  
 185 powder in 10 ml of Dragoxat and stirring for 2 h with a  
 186 magnetic stirrer. In order to avoid clogging of the micro-  
 187 fluidic channel, the undissolved TC remaining in the solu-  
 188 tion after mixing is eliminated using a filter of size  $\sim 1$   $\mu\text{m}$ .

## 189 2.2 Microsystem design and fabrication

190 We have designed a microsystem with a double flow-  
 191 focusing junction as illustrated in Fig. 1. The HSA solution  
 192 is injected in the central channel (1). The Dragoxat is  
 193 injected in the two lateral channels (2) making a  $80^\circ$  angle  
 194 with channel 1 [the angle value was selected from our  
 195 previous work (He et al. 2010); it contributes to prevent  
 196 contact between the HSA solution and the wall]. Droplets  
 197 are formed at the first junction between channel 1 and  
 198 channels 2. Compared to a T-junction this flow focusing  
 199 configuration limits the possible adsorption of the central  
 200 droplet phase on the walls. After the junction, the central  
 201 channel has the same dimensions as channel 1. The cross-  
 202 linking phase, i.e. the solution of terephthaloyl chloride in  
 203 Dragoxat, is injected at the second junction through the two  
 204 lateral channels (3), which also make a  $80^\circ$  angle with the  
 205 central channel. The droplet, surrounded by the cross-  
 206 linking phase, then flows in channel 4, the waviness of  
 207 which favors mixing and enables a homogeneous concen-  
 208 tration of the cross-linking agent. The cross-linking time is  
 209 controlled by the length and cross-section of channel 4. Its  
 210 cross-section is larger than that of channel 1 to slow the  
 211 microcapsules down. A cylindrical channel of internal  
 212 radius  $R$  is inserted inside channel 5 for microcapsule



**Fig. 1** Microfluidic system for microcapsule fabrication and characterization

213 characterization. Finally, the microcapsules are collected in  
 214 reservoir 6.

215 The main parameters for droplet fabrication are the  
 216 channel cross-section dimensions and the flow rates of  
 217 central and lateral fluids.

218 The procedure of fabrication of the PDMS microsystem  
 219 is classical. The mould master, which consists of a SU8  
 220 photoresist patterned on a Silicon wafer, is manufactured  
 221 by photolithography. Briefly, the SU8 photoresist is  
 222 deposited on a silicon wafer by spin coating. Successive  
 223 spin coating applications of the SU-8 photoresist allow the  
 224 fabrication of multi-height microfluidic channels through  
 225 mask alignment and multiple UV exposures (multiple UV  
 226 lithographies were used to create the higher height  $h_4$  in  
 227 the channel sections 4, 5 and 6, see Table 1 to increase cross-  
 228 linking time). After exposure, the system is immersed and  
 229 agitated in a 1-Methoxy-2-propyl acetate developer solu-  
 230 tion to dissolve the unexposed parts.

231 A mixture of PDMS with curing agent (10:1 mass ratio)  
 232 is then poured onto the mold master. The system is degassed  
 233 to remove the air bubbles and heated in the oven at 70 °C  
 234 for 2 h. The PDMS mould is peeled off the master and five  
 235 holes are drilled into it for the injection of the solutions and  
 236 collection of the capsules. The PDMS is bonded onto a glass  
 237 substrate using plasma treatment to close the channels. The  
 238 system is used a few days after fabrication to allow the  
 239 PDMS to retrieve its hydrophobicity.

240 Three chips have been designed with width, depth and  
 241 length of channel  $i$  denoted  $W_i$ ,  $h_i$  and  $L_i$ , respectively. The  
 242 geometric parameters of the dry chips under vacuum are  
 243 given in Table 1.

## 244 2.3 Experimental observation technique and PDMS 245 swelling problem

246 To visualize the experiments, the microsystem is placed  
 247 under a microscope (Leica, Germany). Images are recorded

**Table 1** Dry chip geometric parameters

System	$W_1$ ( $\mu\text{m}$ )	$W_2$ ( $\mu\text{m}$ )	$h_1$ ( $\mu\text{m}$ )	$W_4$ ( $\mu\text{m}$ )	$h_4$ ( $\mu\text{m}$ )	$L_4$ (cm)
1	103	215	115			
2	103	215	115	300	200	68
3	109	110	88	290	320	100

System 1 is devoid of a wavy channel

248 using a high-speed camera (Photron, Fastcam SA3), which  
249 has a nominal frame rate of 2000 frames/s. Visualizations  
250 are performed under the  $20\times$  magnification. The image  
251 calibration is achieved using a Malassez (Marienfeld,  
252 Germany)  $50\times 50\ \mu\text{m}^2$ . The calibration indicates that 42  
253 pixels correspond to  $50\ \mu\text{m}$ .

254 Experimental observations show that the channel width  
255 decreases when Dragoxat is injected into the microsystem  
256 (Fig. 2a, b). PDMS swelling has previously been observed  
257 in the case of contact with ethyl acetate (Ng Lee et al.  
258 2003; Nguyen et al. 1999) and silicone oil (Anna et al.  
259 2003). Using the image calibration, we estimate the chan-  
260 nel width before and after Dragoxat injection. For each  
261 experimental setup, we measure the modified width of the  
262 central, lateral and wavy channels,  $W'_1, W'_2$  and  $W'_4$ ,  
263 respectively. As for the height of the channels, no direct  
264 measurement can be made. We have therefore assumed the  
265 modified depth of the central channel to be  $h'_1 = h_1 -$   
266  $(W_1 - W'_1)/2$ , since swelling occurs only along one side of  
267 the channel (the bottom surface is the glass substrate).  
268 Similarly, the modified depth of the wavy channel is  
269 assumed to be  $h'_4 = h_4 - (W_4 - W'_4)/2$ .

#### 270 2.4 Experimental procedure

271 In order to study the droplet generation process, channel 3  
272 is first closed in microchip 1.

273 At first, the dragoxat is injected into the lateral channels  
274 2 using a two-channel syringe pump (KD system) leading  
275 to equal flow rates  $Q_2$  in each branch. Then the serum  
276 albumin solution is injected into channel 1 at a flow rate  $Q_1$   
277 using a second syringe pump.

278 To obtain the cross section of the drop in its axial plane,  
279 the microscope is focused on the middle plane of the

channel. The drop size is characterized by the droplet  
280 length  $L_g$  in the central channel downstream of the junction  
281 (Fig. 3).  
282


283 To produce microcapsules, we open channel 3 and first  
284 inject the pure Dragoxat solution with equal flow rates  $Q_3$   
285 in each branch to stabilize the flow. Then, the cross-linking  
286 phase is injected with the same flow rates  $Q_3$ . As the cross-  
287 section of channel 4 is larger than that of channel 1, the  
288 microcapsules take a spherical shape from the second  
289 junction onwards. The microcapsule size is equal to the  
290 microdroplet size measured after the first junction, as their  
291 volume only differs by a thin membrane. The radius of the  
292 undeformed (i.e. spherical) microcapsule  $a$  is obtained  
293 from its volume. The volume is calculated from the  
294 deformed shape of Fig. 3, assuming the capsule to be an  
295 ellipsoid with diameters  $L_g, W'_1, h'_1$ . The membrane for-  
296 mation occurs while the microdroplet is traveling inside the  
297 wavy channel. The microdroplet diameter is of order  
298  $200\ \mu\text{m}$ , while the cross dimension of the channel is of  
299 order  $300\ \mu\text{m}$ . The velocity of a centered microdroplet and  
300 later of the microcapsule will be slightly larger than the  
301 mean flow velocity, but it is difficult to determine with  
302 precision. Consequently, the order of magnitude of the  
303 cross-linking time  $t_r$  is evaluated from the mean flow  
304 velocity in the wavy channel.

$$t_r = L_4 \frac{W'_4 h'_4}{Q_1 + 2Q_2 + 2Q_3} \quad (1)$$


306 In order to measure the elasticity of the capsule  
307 membrane, a glass cylindrical microchannel with internal  
308 radius  $R = 100\ \mu\text{m}$  is inserted into channel 5 to deform the  
309 microcapsules. The camera and microscope are positioned  
310 on channel 5 to measure simultaneously the velocity and the  
311 deformed profile of the flowing capsules. These results are

**Fig. 2** Decrease in the channel width of microsystem 1 in presence of Dragoxat.

**a** Microsystem under vacuum;  
**b** microsystem in presence of Dragoxat and **c** microsystem after dragoxat removal and channel cleaning







**Fig. 3** Formation of the drop at the first junction

312 then analyzed with the procedure described in our previous  
 313 works (Lefebvre et al. 2008; Chu et al. 2011) and briefly  
 314 summarized below in the membrane characterization  
 315 section. In practice, we had to wait for a few minutes to  
 316 achieve a stable flow configuration for the microdroplet  
 317 formation and 20 min more to achieve stable microcapsules  
 318 formation.

**3 Results**


**3.1 Control of the capsule size**

321 We first close channel 3 to study the variation of the drop  
 322 size as a function of the flow rate ratio between the  
 323 central and lateral channels. The results measured in  
 324 chips 1 and 2 are shown in Fig. 4. The normalized drop  
 325 length  $L_g W'_2 / h'_1 W'_1$  increases linearly with the flow rate  
 326 ratio  $Q_1 / Q_2$ . It follows the linear regression curve

$$\frac{L_g W'_2}{h'_1 W'_1} \approx 7 \frac{Q_1}{Q_2} + 4.9 \quad (2)$$

329 In a previous study conducted with the same fluid couple,  
 330 we had already shown the linear dependency of the  
 331 normalized drop length with the flow rate ratio (He et al.  
 332 2010). The slope of the regression had, however, been  
 333 found to be about half the present value. A few reasons  
 334 may account for the discrepancy. One of them is the  
 335 swelling phenomenon, which had not been taken into  
 336 account in the previous study. Since then, we have also  
 337 calibrated the actual flow rate values provided by the  
 338 pumps to account for the time fluctuations. Finally, we  
 339 have improved the image analysis by enhancing the lumi-  
 340 nosity and contrast using a more sensitive camera and new  
 341 microscope objectives. Even though we have optimized the  
 342 quality of the measurements, a dispersion is still observed  
 343 (Fig. 4). During the microdroplet formation, we calculated  
 344 a standard deviation of 7 % on the measured droplet length  
 345  $L_g$ . In addition, resulting from independent experiments the  
 346 total standard deviation was calculated at 20 %.

347 When the cross-linking phase is injected through chan-  
 348 nel 3, it is verified that it has no influence on the drop  
 349 formation in the upstream bifurcation. In particular, the  
 350 drop size does not change.



**Fig. 4** Variation of the normalized droplet length with the flow rate ratio  $Q_1 / Q_2$  in microsystems 1 and 2

**3.2 Residence time and polymerization**


352 The cross-linking degree is a function of the residence time  
 353 of the capsules in the wavy channel (channel 4). The res-  
 354 idence time can be modified by varying either the flow rate  
 355 in the channel or the channel length. Different flow con-  
 356 ditions have been studied. Using chip 2, we have set  $Q_2$  to  
 357 33  $\mu\text{L}/\text{min}$  and  $Q_3$  to 12.5  $\mu\text{L}/\text{min}$ , and varied  $Q_1$  from 7 to  
 358 15  $\mu\text{L}/\text{min}$  to change the capsule size. These conditions  
 359 lead to a cross-linking time of order  $t_r = 23$  s. A typical  
 360 capsule deformed profile in channel 5 is shown in Fig. 5a.  
 361 Then using chip 3 with the longer wavy channel, we have  
 362 first set  $Q_2 = 25$   $\mu\text{L}/\text{min}$ ,  $Q_3 = 17$   $\mu\text{L}/\text{min}$ , and varied  $Q_1$   
 363 from 6 to 9.2  $\mu\text{L}/\text{min}$ . The cross-linking time is found to be  
 364 of order  $t_r = 60$  s. Otherwise, imposing  $Q_2 = 22$   $\mu\text{L}/\text{min}$ ,  
 365  $Q_3 = 14$   $\mu\text{L}/\text{min}$ , and varying  $Q_1$  from 5 to 8  $\mu\text{L}/\text{min}$ , we  
 366 have obtained a cross-linking time of order  $t_r = 70$  s. The  
 367 corresponding capsule profile are shown in Fig. 5b, c,  
 368 respectively.

369 We note that, whereas the capsule profile in Fig. 5a, is  
 370 smooth, the other two profiles (Fig. 5b, c) are wrinkled.  
 371 The very presence of the wrinkles proves that a thin solid  
 372 membrane has been formed and that the capsule has not  
 373 been gelled throughout. Indeed, a liquid-liquid interface is  
 374 always smooth due to the surface tension. The folds are a  
 375 consequence of the compression of the membrane in the  
 376 azimuthal direction, which leads to buckling. This phe-  
 377 nomenon has been also observed in a numerical model of  
 378 the flow of an initially spherical capsule in a cylindrical  
 379 tube (Hu et al. 2012). We conclude that for a long enough  
 380 residence time in channel 4, the cross-linking of the  
 381 membrane has time to occur.

**3.3 Membrane characterization**

382  
 383 An inverse method is used to deduce the capsule shear  
 384 modulus from the experimental measurements on capsules

Author Proof



**Fig. 5** Pictures of microcapsules fabricated in situ and flowing down the cylindrical channel. **a**  $t_r = 23$  s,  $a/R = 1.08$ ; **b**  $t_r = 60$  s,  $a/R = 1.17$ ; **c**  $t_r = 70$  s,  $a/R = 0.95$ . Scale bar is 100  $\mu\text{m}$

385 flowing in the cylindrical pore of channel 5 (Lefebvre et al.  
386 2008; Chu et al. 2011). The method is based on the use of a  
387 numerical model of the flow of an initially spherical cap-  
388 sule (radius  $a$ ) in a small cylindrical channel with radius  
389  $R$  (Lefebvre et al. 2008; Hu et al. 2012). This model takes  
390 into account the fluid–structure interactions which lead to  
391 the large deformation (and eventual buckling) of the cap-  
392 sule membrane. As shown recently in our recent study  
393 (Hu et al. 2012), it is possible to use an axisymmetric  
394 model (Lefebvre et al. 2008), even in the case of large size  
395 ratios  $a/R$  and membrane buckling. The input parameters of  
396 the numerical model are the size ratio  $a/R$ , the membrane  
397 constitutive law and the flow strength normalized by the  
398 membrane elastic resistance  $\mu Q/\pi R^2 G_s$ , where  $\mu$  is the  
399 external flow viscosity,  $Q/\pi R^2$  is the mean flow velocity in  
400 the tube and  $G_s$  is the surface shear elastic modulus of the  
401 capsule membrane. The output of the model is the capsule  
402 deformed profile and velocity.

403 The identification procedure has been described in detail  
404 previously (Chu et al. 2011). It consists of determining the  
405 deformed capsule profile and velocity inside the cylindrical  
406 tube. Note that the leakage flow in the gap around the  
407 cylindrical tube has no influence as the measurement is  
408 done inside the tube. We then perform contour analysis  
409 using the software ImageJ and determine the capsule vol-  
410 ume and initial radius  $a$  assuming axisymmetry. The con-  
411 tour determination is estimated to lead to a 2 % error on the  
412 size ratio. We then characterize the capsule deformation by  
413 means of the axial profile length  $L$  and the meridional  
414 profile area  $S$ . Assuming that the membrane constitutive  
415 law is the neo-Hookean law, we set the value of the size  
416 ratio  $a/R$  and search a database for the numerical capsule  
417 deformed profile with the same values of  $L$  and  $S$  as  
418 the experimental ones. This yields the normalized flow  
419 strength and the ratio between the capsule velocity (mea-  
420 sured) and the fluid mean velocity. We can then deduce the  
421 membrane shear elastic modulus  $G_s$ .


422 The values of shear modulus obtained for the three times  
423 of cross-linking are indicated in Fig. 6 as a function of the  
424 size ratio  $a/R$ . We find that, for a cross-linking time

425  $t_r = 23$  s, the mean value of the shear modulus is 425  
426  $G_s = 0.004$  N/m with a standard deviation of 0.001 N/m. 426  
427 This value is of the same order as the surface tension 427  
428 between Dragoxat and the HSA solution (0.006 N/m). 428  
429 A cross-linking time of 23 s is therefore too short for a 429  
430 solid membrane to form around the droplet. For the longer 430  
431 cross-linking times, the mean shear modulus of the capsule 431  
432 membrane is found to be  $G_s = 0.011 \pm 0.002$  N/m for 432  
433  $t_r = 60$  s, and  $G_s = 0.018 \pm 0.002$  N/m for  $t_r = 70$  s. 433  
434 These values are significantly larger than the surface ten- 434  
435 sion between Dragoxat and the HSA solution, which con- 435  
436 firms that a membrane is formed around the drop, as was 436  
437 already surmised from the observation of wrinkles. 437


438 Finally, the evolution of the shear elastic modulus with the 438  
439 cross-linking time is shown in Fig. 7. We find that the shear 439  
440 modulus of the microcapsule membrane increases steeply 440  
441 with the cross-linking time, as was also observed in the case 441  
442 of microcapsules made with an ovalbumin membrane (Chu 442  
443 et al. 2011). The longer the reactants remain in contact, the 443  
444 higher the cross-linking degree in the membranes and then 444  
445 the higher the shear modulus. In addition, this result is in 445  
446 good agreement with our previous findings in bulk emulsion 446  
447 (Edwards-Lévy et al. 1993) showing that for a reaction pH of 447  
448 9.8, an increase in cross-linking time produced more inten- 448  
449 sely cross-linked serum albumin microcapsules (less free 449  
450 amino groups, higher ester and anhydride content). 450

#### 4 Discussion 451

452 We have designed and used a single microfluidic system to 452  
453 fabricate and directly characterize microcapsule popula- 453  
454 tions. The microdroplet size depends only on the flow rate of 454  
455 the dispersed and continuous phases. The normalized drop 455  
456 length follows the linear regression curve as proposed in the 456  
457 literature (He et al. 2010). However, the slope coefficient is 457  
458 twice that found in our previous work. Various phenomena 458  
459 may account for this discrepancy, such as PDMS swelling 459  
460 when in contact with Dragoxat, the flow rate irregularity of 460  
461 the pump setting and the fuzziness of the droplet image. 461



**Fig. 6** Shear modulus of the microcapsule membrane fabricated after **a** 23 s; **b** 60 s; **c** 70 s as a function of the size ratio  $a/R$



**Fig. 7** Variation of the shear modulus of the albumin membrane of microcapsule as a function of the cross-linking time

462 The mechanical properties of the microcapsule mem-  
 463 brane are characterized with an inverse method. The mean  
 464 shear modulus of the capsules fabricated after 23 s of  
 465 cross-linking is of the order of the surface tension between  
 466 the HSA and Dragoxat solutions: such a low cross-linking  
 467 time is too short for an elastic membrane to form around  
 468 the droplet. After 60 s of cross-linking, microcapsules with  
 469 wrinkles on the membrane are formed. The membrane  
 470 shear modulus increases when the cross-linking time  
 471 increases to 70 s. This study shows that the microsystem  
 472 can be used to combine the fabrication of controlled size  
 473 microcapsules and their characterization. Indeed, the  
 474 microfluidic system offers the advantages to fabricate a  
 475 calibrated capsule population through the formation of  
 476 droplets of a defined size, followed by a controlled cross-  
 477 linking reaction. Furthermore, the proposed design enables  
 478 to measure the geometric and mechanical properties of the  
 479 capsules using *in situ* visualizations.

480 It has not been possible to compare the mechanical  
 481 properties of serum albumin membrane microcapsules

482 fabricated with the present method (microfluidic technique)  
 483 and bulk agitation. In bulk agitation, we were not able to  
 484 collect a stable capsule population below 2 min of cross-  
 485 linking. For a bulk cross-linking time of 5 min, the serum  
 486 albumin capsules were stable, but too rigid to be flowed in  
 487 a microtube and deformed under the hydrodynamic forces.  
 488 The only points of reference that can be used for compar-  
 489 ison are therefore the measurements of populations of  
 490 microcapsules made with an ovalbumin membrane under  
 491 bulk agitation. Chu et al. (2011) found that the shear  
 492 modulus values range from 0.03 to 0.2 N/m according to  
 493 the pH and the reaction time. Practically, it appears that  
 494 the present method will not enable the characterization of  
 495 capsules with a surface shear modulus much larger than  
 496 0.2 N/m. Higher shear stresses would need to be gener-  
 497 ated in the microfluidic channel to deform more rigid micro-  
 498 capsules, but the present setup cannot sustain them. The  
 499 present measurements have found comparable values  
 500 (0.011–0.018 N/m for  $t_r = 60$ –70 s) in the case of serum  
 501 albumin membrane. It is therefore likely that the micro-  
 502 fluidic technique allows for capsule fabrication using short  
 503 times of cross-linking ( $t_r = 60$ –70 s), while the conven-  
 504 tional technique based on agitation requires a longer time  
 505 to allow a perfect mixing of the cross-linking solution with  
 506 the continuous phase of the emulsion (at least  
 507  $t_r = 5$ –30 min). Thus the microfluidic fabrication appears  
 508 as a new process, which could complement the bulk pro-  
 509 cesses and thus enlarge the spectrum of populations of  
 510 microcapsules that can be designed and produced.

511 Despite the fact that the microcapsule populations  
 512 appear to be stable in the reservoir, we have not yet  
 513 included protocols to collect and clean the microcapsules.  
 514 We therefore cannot guarantee their full stability outside  
 515 the microsystem. This is a key point since the excess of  
 516 cross-linking agent must be removed to yield a functional  
 517 capsule population. Another perspective for future devel-  
 518 opment of the microsystem is the insertion of a feedback  
 519 control on the flow rates of the different phases according  
 520 to the measured membrane properties. It would enable the  
 521 optimization of the fabrication conditions on demand.

522 **5 Conclusion**

523 We have proposed a microfluidic device to create and  
 524 characterize microcapsule populations. The microcapsules  
 525 are fabricated in a double Y-junction geometry. The shear  
 526 modulus of the membrane of the microcapsules are obtained  
 527 from an inverse method coupling experimental and numerical  
 528 approaches. The numerical model simulates the fluid-  
 529 structure interactions in the case of a capsule flowing in a  
 530 cylindrical tube. The microcapsule deformation is measured  
 531 experimentally in a glass capillary located downstream of the  
 532 Y-junctions. We then search the numerical database for the  
 533 parameters that leads to the capsule deformation that is  
 534 measured and identify them using a best fit method. We  
 535 presently show that a microcapsule inline fabrication process  
 536 can be successfully coupled with a characterization method.  
 537 Setting up a technique to collect and wash the microcapsules  
 538 will be the next step of our development to propose a func-  
 539 tional fabrication process.

540 **Acknowledgments** This work was supported by the Conseil  
 541 Regional de Picardie (projects  $\mu$ FIEC and MODCAP).

542 **References**

543 Andry M-C, Edwards-Lévy F, Lévy M-C (1996) Free amino group  
 544 content of serum albumin microcapsules III: a study at low pH  
 545 values. *Int J Pharm* 128:197–202  
 546 Anna SL, Bontoux N, Stone HA (2003) Formation of dispersions  
 547 using 'flow focusing' in microchannels. *Appl Phys Lett*  
 548 82:364–366  
 549 Callewaert M, Millot JM, Lesage J, Laurent-Maquin D, Edwards-  
 550 Lévy F (2009) Albumin-alginate microspheres: role of structure  
 551 in binding and release of the krfl peptide. *Int J Pharm*  
 552 366:103–110  
 553 Carin M, Barthès-Biesel D, Edwards-Lévy F, Postel C, Andrei DC  
 554 (2003) Compression of biocompatible liquid-filled HSA-alginate  
 555 capsules: determination of the membrane mechanical properties.  
 556 *Biotechnol Bioeng* 82:207–212  
 557 Chu TX, Salsac AV, Leclerc E, Barthès-Biesel D, Wurtz H, Edward-  
 558 Lévy F (2011) Comparison between measurements of elasticity  
 559 and free amino group content of ovalbumin microcapsule  
 560 membranes: discrimination of the cross-linking degree. *J Colloid*  
 561 *Interf Sci* 355:81–88  
 562 De Kruif CG, Weinbreck F, De Vries R (2004) Complex coacervation  
 563 of proteins and anionic polysaccharides. *Curr Opin Colloid Interf*  
 564 *Sci* 9:340–349  
 565 Edwards-Lévy F (2011) Microparticulate drug delivery systems based  
 566 on serum albumin. In: *Serum albumin: structure, functions, and*  
 567 *health impact*. Nova Science  
 568 Edwards-Lévy F, Andry M-C, Lévy M-C (1993) Determination of  
 569 free amino group content of serum albumin microcapsules using  
 570 trinitrobenzenesulfonic acid: effect of variations in polycondensa-  
 571 tion pH. *Int J Pharm* 96:85–90  
 572 Edwards-Lévy F, Andry M-C, Lévy M-C (1994) Determination of  
 573 free amino group content of serum albumin microcapsules: II.  
 574 Effect of variation time and in terephthaloyl chloride concen-  
 575 tration. *Int J Pharm* 103:253–257

Fery A, Weinkamer R (2007) Mechanical properties of micro and  
 576 nanocapsules: Single-capsule measurements. *Polym Adv Tech-*  
 577 *nol* 48:7221–7235  
 578 Garstecki P, Fuerstman MJ, Stone HA, Whitesides GM (2006)  
 579 Formation of droplets and bubbles in a microfluidic T-junction-  
 580 scaling and mechanism of break-up. *Lab Chip* 6:437–446  
 581 Gautier A, Carpentier B, Dufresne M, Vu Dinh Q, Paulier P, Legallais  
 582 C (2011) Impact of alginate type and bead diameter on mass  
 583 transfers and the metabolic activities on encapsulated c3a cells in  
 584 bioartificial liver applications. *Eur Cell Mater* 21:94–106  
 585 Gibbs BF, Kermasha S, Alli I, Mulligan CN (1999) Encapsulation in  
 586 the food industry: a review. *Int J Food Sc. Nutr* 50:213–224  
 587 He P, Barthès-Biesel D, Leclerc E (2010) Flow of two immiscible  
 588 liquids with low viscosity in y shaped microfluidic systems:  
 589 effect of geometry. *Microfluid Nanofluid* 9:293–301  
 590 Hu X-Q, Salsac A-V, Barthès-Biesel D (2012) Flow of a spherical  
 591 capsule in a pore with circular or square cross-section. *J Fluid*  
 592 *Mech* (to appear)  
 593 Huang K-S, Liu M-K, Wu C-H, Yen Y-T, Lin Y-C (2007) Calcium  
 594 alginate microcapsule generation on a microfluidic system  
 595 fabricated using the optical disk process. *J Micromech Microeng*  
 596 17:1428–1434  
 597 Hurteaux R, Edwards-Lévy F, Laurent-Maquin D, Lévy M-C (2005)  
 598 Coating alginate microspheres with a serum albumin-alginate  
 599 membrane: application to the encapsulation of a peptide. *Eur J*  
 600 *Pharm Sci* 24:187–197  
 601 Kissel T, Maretschek S, Packhaser C, Schnieders J, Seidel N (2006)  
 602 Microencapsulation techniques for parenteral depot systems and  
 603 their application in the pharmaceutical industry. In: Benita S (ed)  
 604 *Microencapsulation—methods and industrial applications*, 2nd  
 605 edn. Taylor and Francis  
 606 Lefebvre Y, Leclerc E, Barthès-Biesel D, Walter J, Edwards-Lévy F  
 607 (2008) Flow of artificial microcapsules in microfluidic channels:  
 608 a method for determining the elastic properties of the membrane.  
 609 *Phys Fluids* 20:1–10  
 610 Lévy MC, Lefebvre S, Rahmouni M, Andry MC, Manfait M (1991)  
 611 Fourier transform infrared spectroscopic studies of human serum  
 612 albumin microcapsules prepared by interfacial cross-linking with  
 613 terephthaloylchloride: Influence of polycondensation ph on  
 614 spectra and relation with microcapsule morphology and size.  
 615 *J Pharm Sci* 80:578–585  
 616 Liu L, Yang J-P, Ju X-J, Xie R, Yang L, Liang B, Chu L-Y (2009)  
 617 Microfluidic preparation of monodisperse ethyl cellulose hollow  
 618 microcapsules with non-toxic solvent. *J Colloids Interf Sci*  
 619 336:100–106  
 620 Mercadé-Prieto R, Zhang Z (2012) Mechanical characterization of  
 621 microspheres, capsules, cells and beads: a review. *J Microencap-*  
 622 *sulation* 29:277–285  
 623 Miyazawa K, Yajima I, Kaneda I, Yanaki T (2000) Preparation of a  
 624 new soft capsule for cosmetics. *J Cosmet Sci* 51:239–252  
 625 Needham D, Zhelev DV (1996) The mechanochemistry of lipid  
 626 vesicles examined by micropipet manipulation technique. *Surf*  
 627 *Sci* 62:373–444  
 628 Ng Lee J, Park C, Whitesides GM (2003) Solvent compatibility of  
 629 poly(dimethylsiloxane)-based microfluidic devices. *Anal Chem*  
 630 75:6544–6554  
 631 Nguyen QT, Bendjama Z, Clment R, Ping Z (1999) Poly(dimethyl-  
 632 siloxane) crosslinked in different conditions. Part I: sorption  
 633 properties in water-ethyl acetate mixtures. *Phys Chem*  
 634 1:2761–2766  
 635 Poux M, Canselier J.P (2004) Techniques et appareillage, procédés  
 636 d'émulsification. *Technique de l'ingénieur*, Chapitre 3. J2153.  
 637 Techniques de l'ingénieur  
 638 Sawalha H, Schron K, Boom R (2011) Biodegradable polymeric  
 639 microcapsules: preparation and properties. *Chem Eng J* 169:  
 640 1–10  
 641



642 Thorsen T, Roberts RW, Arnold FH, Quake SR (2001) Dynamic  
 643 pattern formation in a vesicle-generating microfluidic device.  
 644 Phys Rev Lett 86:4163–4166  
 645 Yeh C-H, Zhao Q, Lee S-J, Lin Y-C (2009) Using a t-junction  
 646 microfluidic chip for monodisperse calcium alginate micropar-  
 647 ticles and encapsulation of nanoparticles. Sensor Actuat A Phys  
 648 151:231–236

Yobas L, Martens S, Ong W-L, Ranganathan N (2006) High-  
 performance flow-focusing geometry for spontaneous generation  
 of monodispersed droplets. Lab Chip 6:1073–1079

Zhang H, Tumarkin E, Peerani R, Nie Z, Sullan RMA, Walker GC,  
 Kumacheva E (2006) Microfluidic production of biopolymer  
 microcapsules with controlled morphology. J Am Chem Soc  
 128:12205–12210

649  
 650  
 651  
 652  
 653  
 654  
 655  
 656

Author Proof

UNCORRECTED PROOF